Cirrhosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：49頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Cirrhosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Cirrhosis - Pipeline Review, H1 2014’, provides an overview of the Cirrhosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cirrhosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cirrhosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Cirrhosis - Pipeline Review, H1 2014’, provides an overview of the Cirrhosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cirrhosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cirrhosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cirrhosis Overview 6
Therapeutics Development 7
Pipeline Products for Cirrhosis - Overview 7
Pipeline Products for Cirrhosis - Comparative Analysis 8
Cirrhosis - Therapeutics under Development by Companies 9
Cirrhosis - Therapeutics under Investigation by Universities/Institutes 10
Cirrhosis - Pipeline Products Glance 11
Clinical Stage Products 11
Unknown Stage Products 12
Cirrhosis - Products under Development by Companies 13
Cirrhosis - Products under Investigation by Universities/Institutes 14
Cirrhosis - Companies Involved in Therapeutics Development 15
Ocera Therapeutics, Inc. 15
Hyperion Therapeutics, Inc. 16
PharmaIN Corporation 17
Alfact Innovation 18
Cirrhosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ornithine phenylacetate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
glycerol phenylbutyrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ALF-5755 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PGC Based Natriuretic Peptides - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cirrhosis - Recent Pipeline Updates 38
Cirrhosis - Dormant Projects 42
Cirrhosis - Product Development Milestones 43
Featured News & Press Releases 43
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 43
Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan 43
Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis 44
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 44
Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD 44
Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD 46
Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Number of Products under Development for Cirrhosis, H1 2014 7
Number of Products under Development for Cirrhosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Unknown Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H1 2014 15
Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H1 2014 16
Cirrhosis - Pipeline by PharmaIN Corporation, H1 2014 17
Cirrhosis - Pipeline by Alfact Innovation, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Cirrhosis Therapeutics - Recent Pipeline Updates, H1 2014 38
Cirrhosis - Dormant Projects, H1 2014 42
List of Figures
Number of Products under Development for Cirrhosis, H1 2014 7
Number of Products under Development for Cirrhosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cirrhosis Overview 6
Therapeutics Development 7
Pipeline Products for Cirrhosis - Overview 7
Pipeline Products for Cirrhosis - Comparative Analysis 8
Cirrhosis - Therapeutics under Development by Companies 9
Cirrhosis - Therapeutics under Investigation by Universities/Institutes 10
Cirrhosis - Pipeline Products Glance 11
Clinical Stage Products 11
Unknown Stage Products 12
Cirrhosis - Products under Development by Companies 13
Cirrhosis - Products under Investigation by Universities/Institutes 14
Cirrhosis - Companies Involved in Therapeutics Development 15
Ocera Therapeutics, Inc. 15
Hyperion Therapeutics, Inc. 16
PharmaIN Corporation 17
Alfact Innovation 18
Cirrhosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ornithine phenylacetate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
glycerol phenylbutyrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ALF-5755 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PGC Based Natriuretic Peptides - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cirrhosis - Recent Pipeline Updates 38
Cirrhosis - Dormant Projects 42
Cirrhosis - Product Development Milestones 43
Featured News & Press Releases 43
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 43
Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan 43
Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis 44
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 44
Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD 44
Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD 46
Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Number of Products under Development for Cirrhosis, H1 2014 7
Number of Products under Development for Cirrhosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Unknown Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H1 2014 15
Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H1 2014 16
Cirrhosis - Pipeline by PharmaIN Corporation, H1 2014 17
Cirrhosis - Pipeline by Alfact Innovation, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Cirrhosis Therapeutics - Recent Pipeline Updates, H1 2014 38
Cirrhosis - Dormant Projects, H1 2014 42
List of Figures
Number of Products under Development for Cirrhosis, H1 2014 7
Number of Products under Development for Cirrhosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
